Advancing Drug Development by Reducing Reliance on Animal Testing summarizes a hybrid public meeting held on February 26, 2026, where the FDA, patient advocates, regulated industry, and researchers explored strategies to reduce reliance on traditional animal testing. Using inhalation toxicology as a case study, participants discussed how to accelerate progress and align global regulatory expectations without hindering drug development.
The report includes three key areas of focus:
- Exploring FDA-supported New Approach/Alternative Methodologies
- Examining new strategies and weight of evidence approaches to support human safety
- Addressing how current reliance on rodent inhalation toxicology may delay patient access to critical inhaled therapies
